At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,000 enrolled
Drug / intervention
mRNA-1273.712 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
In Brief
A Phase 4 clinical trial evaluating mRNA-1273.712 and Placebo for Healthy Volunteers. Completed, enrolled 1,000 participants across 24 sites.
Detailed Summary
The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
Enrollment StartOct 2024
First PostedOct 2024
Primary CompletionJan 2025
TodayJul 2026
First PostedOct 10, 2024
Enrollment StartOct 8, 2024
Primary CompletionJan 20, 2025
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 1.7 years ago
Interventions
mRNA-1273.712biological
Intramuscular (IM) injection.
Placebobiological
Sodium chloride for IM injection.